Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

January 5, 2018: By Jon Swedien

Spark Therapeutics has priced Luxturna, its breakthrough gene therapy, at $850 thousand, or $425 thousand per eye, the Philadelphia company said in an SEC filing Jan. 3.

Some Wall Street analysts had predicted Luxturna (voretigene neparvovec) would be priced at $1 million. The US FDA approved Luxturna in December for the treatment of retinal dystrophies caused by mutations in the RPE65 gene.

Luxturna is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease, and the first adeno-associated virus (AAV) vector gene therapy approved in the US, according to Spark.
Spark also outlined its plan to offer a trio of financing plans to help make the drug affordable.

One plan is an “outcomes-based rebate arrangement that aligns with longer-term efficacy of Luxturna,” the company said. Spark said it will share risk with certain health insurers by paying rebates if patient outcomes fail to meet a specified threshold in short-term (30 to 90 days) and longer-term (30 months) efficacy measures. Spark has reached an agreement with Harvard Pilgrim to offer this rebate arrangement.

Spark also proposed a contracting model, under which a commercial payer or payer’s specialty pharmacy, rather than the treatment center, would purchase Luxturna. The payer would provide coverage for its members consistent with US FDA labeling, expedite benefits processing, and cap patient out-of-pocket amounts at in-network limits. Separately, the payer would agree with the treatment center on reimbursement that is commensurate with the type of specialized medical care required to deliver Luxturna. Spark would assume all drug in-transit, storage, and handling risks. Spark is working with affiliates of Express Scripts to enable this contracting model.

Spark also said it is in discussions with Centers for Medicare & Medicaid Services (CMS) on an annuity-like model that would spread payments over multiple years, while providing flexibility for greater outcomes-based rebates. Due to current government price reporting requirements, Spark said it is not feasible to offer installment payments or outcomes-based rebates above a certain threshold, but Spark has submitted a proposal to CMS to conduct a demonstration project using this model.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023